Its broader signaling profile perfectly complements the localized pathways of BPC-157 and the matrix-focused research of GHK-Cu
PMCID: PMC1734362 Hoornaert KP, Vereecke I, Dewinter C, Rosenberg T, Beemer FA, Leroy JG, Bendix L, Bjrck E, Bonduelle M, Boute O, Cormier-Daire V, De Die-Smulders C, Dieux-Coeslier A, Dollfus H, Elting M, Green A, Guerci VI, Hennekam RC, Hilhorts-Hofstee Y, Holder M, Hoyng C, Jones KJ, Josifova D, Kaitila I, Kjaergaard S, Kroes YH, Lagerstedt K, Lees M, Lemerrer M, Magnani C, Marcelis C, Martorell L, Mathieu M, McEntagart M, Mendicino A, Morton J, Orazio G, Paquis V, Reish O, Simola KO, Smithson SF, Temple KI, Van Aken E, Van Bever Y, van den Ende J, Van Hagen JM, Zelante L, Zordania R, De Paepe A, Leroy BP, De Buyzere M, Coucke PJ, Mortier GR, et al
Intended strictly for laboratory and in vitro research purposes
When peptides are not synthesized or compounded under proper conditions, they can degrade or become unstable, which might lead to incomplete sequences or harmful byproducts
Our protocols use only regulated, pharmacy-compounded peptides under medical oversight to prioritize safety and long-term performance
Professional medical supervision required for administration and monitoring
